JP2023538736A - Ｂ群レンサ球菌多糖－タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用 - Google Patents

Ｂ群レンサ球菌多糖－タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用 Download PDF

Info

Publication number
JP2023538736A
JP2023538736A JP2023512646A JP2023512646A JP2023538736A JP 2023538736 A JP2023538736 A JP 2023538736A JP 2023512646 A JP2023512646 A JP 2023512646A JP 2023512646 A JP2023512646 A JP 2023512646A JP 2023538736 A JP2023538736 A JP 2023538736A
Authority
JP
Japan
Prior art keywords
kda
polysaccharide
immunogenic composition
capsular polysaccharide
gbs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023512646A
Other languages
English (en)
Japanese (ja)
Inventor
シビル アンダーソン アナリサ
ジョージ コンラッド ドナルド ロバート
シーザー ホーキンス ジュリオ
コダリ スリニヴァス
サイモン ラファエル
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2023538736A publication Critical patent/JP2023538736A/ja
Priority to JP2024207476A priority Critical patent/JP2025029014A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2023512646A 2020-08-26 2021-08-23 Ｂ群レンサ球菌多糖－タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用 Pending JP2023538736A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024207476A JP2025029014A (ja) 2020-08-26 2024-11-28 Ｂ群レンサ球菌多糖－タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063070410P 2020-08-26 2020-08-26
US63/070,410 2020-08-26
US202163229359P 2021-08-04 2021-08-04
US63/229,359 2021-08-04
PCT/IB2021/057714 WO2022043855A1 (en) 2020-08-26 2021-08-23 Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024207476A Division JP2025029014A (ja) 2020-08-26 2024-11-28 Ｂ群レンサ球菌多糖－タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用

Publications (1)

Publication Number Publication Date
JP2023538736A true JP2023538736A (ja) 2023-09-11

Family

ID=77519437

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023512646A Pending JP2023538736A (ja) 2020-08-26 2021-08-23 Ｂ群レンサ球菌多糖－タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用
JP2024207476A Pending JP2025029014A (ja) 2020-08-26 2024-11-28 Ｂ群レンサ球菌多糖－タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024207476A Pending JP2025029014A (ja) 2020-08-26 2024-11-28 Ｂ群レンサ球菌多糖－タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用

Country Status (7)

Country Link
US (1) US20230321212A1 (enExample)
EP (1) EP4203995A1 (enExample)
JP (2) JP2023538736A (enExample)
KR (1) KR20230056727A (enExample)
AU (1) AU2021332183B2 (enExample)
CA (1) CA3192786A1 (enExample)
WO (1) WO2022043855A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20251701A1 (es) * 2022-11-22 2025-07-02 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018087181A (ja) * 2016-11-09 2018-06-07 ファイザー・インク 免疫原性組成物およびその使用
JP2018522978A (ja) * 2015-07-01 2018-08-16 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360897A (en) 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
NZ249704A (en) 1992-02-11 1996-11-26 Jackson H M Found Military Med A two carrier immunogenic construct comprising a 70+ kd molecule conjugated to at least 1 t-dependent antigen, preparation, compositions containing the construct
EP0616034B1 (en) 1993-03-05 2004-10-20 Wyeth Holdings Corporation Plasmid for production of CRM protein and diphtheria toxin
DE122009000058I1 (de) 1993-09-22 2009-12-31 Jackson H M Found Military Med Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
EP0814833B1 (en) 1995-03-22 2003-05-28 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
DE60100814T2 (de) 2000-06-08 2004-07-01 Intercell Biomedizinische Forschungs- Und Entwicklungs Gmbh Immunstimulierende oligodeoxynukleotide
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
AU2002322380B2 (en) 2001-06-07 2006-11-02 Government Of The United States Of America As Represented By The Uniformed Services University Of The Health Sciences Mutant forms of cholera holotoxin as an adjuvant
DE60234695D1 (de) 2001-06-07 2010-01-21 Univ Colorado Mutantenformen von cholera holotoxin als adjuvans
US20040096461A1 (en) * 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
EP1603950A2 (en) 2003-03-17 2005-12-14 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
DK3466982T3 (da) 2005-04-08 2020-08-03 Wyeth Llc Separation af forurenende kontaminanter fra streptococcus pneumoniae-polysaccharid ved ph-manipulation
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP2425856A1 (en) 2005-04-08 2012-03-07 Wyeth LLC Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN102648979B (zh) 2006-10-10 2014-05-14 惠氏公司 肺炎链球菌3型多糖的纯化
EP2129693B1 (en) 2007-03-23 2016-12-07 Wyeth LLC Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
EP3482770B1 (en) 2012-10-03 2020-11-25 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
SI2935299T1 (sl) 2012-12-20 2019-12-31 Pfizer Inc. Postopek glikokonjugacije
RU2692923C2 (ru) * 2015-05-04 2019-06-28 Пфайзер Инк. Конъюгаты полисахарида стрептококка группы В и белка, способы получения конъюгатов, иммуногенные композиции, содержащие конъюгаты, и их применения
US20200254083A1 (en) * 2017-06-16 2020-08-13 Glaxosmithkline Biologicals Sa Method of treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018522978A (ja) * 2015-07-01 2018-08-16 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
JP2018087181A (ja) * 2016-11-09 2018-06-07 ファイザー・インク 免疫原性組成物およびその使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. INFECT. DIS., vol. 180, JPN6024034347, 1999, pages 892 - 895, ISSN: 0005539657 *
J. INFECT. DIS., vol. 186, JPN6024034346, 2002, pages 123 - 126, ISSN: 0005539658 *
MICROBIOL. SPECTR., JPN6024034348, 2019, ISSN: 0005539656 *

Also Published As

Publication number Publication date
EP4203995A1 (en) 2023-07-05
KR20230056727A (ko) 2023-04-27
WO2022043855A1 (en) 2022-03-03
AU2021332183B2 (en) 2025-12-18
US20230321212A1 (en) 2023-10-12
AU2021332183A1 (en) 2023-03-02
JP2025029014A (ja) 2025-03-05
CA3192786A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
JP7587659B2 (ja) Ｂ群レンサ球菌多糖－タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用
JP2025029014A (ja) Ｂ群レンサ球菌多糖－タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用
HK40065014A (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
CN116744964A (zh) B群链球菌多糖-蛋白质缀合物、用于生产缀合物的方法、包含缀合物的免疫原性组合物及其用途
HK40065014B (zh) B族链球菌多糖-蛋白质缀合物、制造缀合物的方法、含缀合物的免疫原性组合物及其用途
HK1245150A1 (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250513